TRUTH LIVES on athttps://sgtreport.tv/
Semaglutide, marketed as Ozempic and Wegovy, has taken the weight loss world by storm. Originally developed to treat Type 2 diabetes, its dramatic weight loss effects quickly caught attention. However, a study analyzing World Health Organization data raises serious concerns about its safety.1
The research reveals a 45% increased risk of suicidal ideation in patients taking semaglutide compared to other medications.2This alarming finding suggests the drug’s effects on mental health are more significant than previously thought.
While the weight loss results can seem miraculous, it’s crucial to understand the many risks before considering this medication. This increased suicide risk warrants urgent investigation.
Individuals with pre-existing mental health conditions may be particularly vulnerable to semaglutide’s psychological side effects. When the analysis focused on patients also taking antidepressants or antianxiety medications, the risk of suicidal ideation was even higher — a 150% to 300% increase in suicidal ideation was found among this group.3
“People with anxiety and depressive disorders may be at higher probability of reporting suicidal ideation when medicated with semaglutide,” the researchers noted.4The drug’s clinical trials often excluded patients with recent major depressive episodes or severe psychiatric disorders. As a result, the full extent of its impact on mental health in vulnerable populations remains unknown.
The popularity of semaglutide has led to widespread off-label use and shortages, and a significant number of reported adverse events involved possible off-label prescriptions. Social media has further fueled its popularity as a lifestyle drug, with many seeking it solely for weight loss.
This trend has even led to illegal trade in semaglutide pens, some of which are counterfeit, posing additional risks to unsuspecting users. “Considering the risk of suicidal ideation in people taking semaglutide off-label, authorities should consider issuing a warning to inform about this risk,” the authors stated.5
The featured study is not the first time Ozempic has raised red flags about suicide. The Icelandic Medicines Agency received multiple reports of suicidal thoughts and self-injury in people using semaglutide, prompting the European Medicines Agency (EMA) to begin reviewing the connection in July 2023.6
With more than 20 million people taking semaglutide and liraglutide, a GLP-1 agonist medication similar to semaglutide, annually, the implications could be devastating to public health.7“Previously, in the approval trials, 9 of the 3384 patients treated with liraglutide (0.27%) had reported suicidal ideation compared with 2 of 1941 patients allocated to the placebo group (0.10%),” researchers explained.8
Source: SGT Report
